Table 2.
Risk of cancer in biologic-naïve and TNFi-treated RA patients compared with the Australian general population, and relative risk in the TNFi treated patients compared to biologic naïve patients
| Risk of cancer in biologic-naïve RA patients compared with the general population | Risk of cancer in TNFi-treated patients compared with the general population | Relative risk (95 % CI) of cancer in TNFi-treated RA patients compared with biologic-naïve RA patients | |||||
|---|---|---|---|---|---|---|---|
| Site | O | E | SIR (95 % CI) | O | E | SIR (95 % CI) | RR (95 % CI)b |
| All invasive cancers | 32 | 23.38 | 1.37 (0.97, 1.94) | 44 | 56.78 | 0.77 (0.58, 1.04) | 0.65 (0.37, 1.17) |
| Melanoma | 5 | 1.84 | 2.72 (1.13, 6.53) | 10 | 4.92 | 2.03 (1.09, 3.78) | 0.54 (0.12, 2.40) |
| Lung | 6 | 2.41 | 2.49 (1.12, 5.53) | 4 | 5.23 | 0.77 (0.29, 2.04) | 0.24 (0.05, 1.17) |
| Lymphoid cancersa | 1 | 1.49 | 0.67 (0.09, 4.76) | 6 | 3.54 | 1.69 (0.76, 3.77) | 4.01 (0.18, 88.19) |
| Colorectal | 2 | 3.41 | 0.59 (0.15, 2.35) | 1 | 7.75 | 0.13 (0.02, 0.92) | 0.06 (0.001, 3.28) |
| Prostate | 5 | 3.38 | 1.48 (0.62, 3.55) | 7 | 7.71 | 0.91 (0.43, 1.90) | 1.21 (0.33, 4.45) |
| Female breast | 5 | 3.32 | 1.51 (0.63, 3.62) | 4 | 10.29 | 0.39 (0.15, 1.04) | 0.17 (0.03, 0.95) |
TNFi tumour necrosis factor inhibitor, RA rheumatoid arthritis, SIR standardised incidence rate, NHL non-Hodgkin’s lymphoma; aLymphoid cancers includes all leukaemias and lymphomas, RR relative risk; badjusted for age, sex, calendar year, smoking status, methotrexate use and prior malignancy